SERPING1 and hereditary angioedema: A subcutaneous (SC) formulation of C1INH, HAEGARDA® (CSL Behring, Marburg, Germany), labeled as Berinert 3000 in the EU, was subsequently approved for the routine prevention of HAE attacks, initially in adolescents and adults22 (EU labeling continues to be for “adolescents” and adults only23) and more recently expanded to patients aged ≥6 years in the United States.24